SHANGHAI, China, Feb. 5 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of Stewart Hen and Ning Zhao to the WuXi PharmaTech Board of Directors.
Dr. Ge Li, WuXi's Chairman and Chief Executive Officer, commented, ''We welcome the addition of Stewart Hen and Ning Zhao to the board. Each brings invaluable expertise as we work to anticipate and meet our customers' evolving needs for improving R&D productivity.''
Mr. Hen is a managing director at Warburg Pincus LLC, a leading global
private equity firm. He focuses on investments in biotechnology and
pharmaceuticals, including pharmaceutical outsourcing. Mr. Hen has more than
17 years of experience in the life sciences industry. Prior to Warburg
Pincus, he was a consultant at McKinsey & Company serving the pharmaceutical
industry. Previously, he worked at Merck in both research and development and
manufacturing. Mr. Hen holds an M.B.A. from the Wharton School of the
Dr. Zhao, one of WuXi's co-founders, is currently lead advisor to the
company's analytical services operations. She was vice president of WuXi's
analytical department from 2004 to 2008 and also established its
Bio-Analytical Services, Core Analytical Services, and Analytical Development
Services departments. She previously worked for Wyeth as a senior research
scientist, for Pharmacopeia as a group leader for the high-throughput analysis
of combinatorial libraries, and for Bristol-Myers Squibb as a site leader in
the Discovery Analytical Sciences department. Dr. Zhao is the co-inventor of
numerous patents and has published and presented more than 36 scientific
papers. With more than 10 years' experience in analytical sciences in the
U.S. pharmaceutical industry, she has received numerous awards, including the
2002 Chemistry Leadership Award from Bristol-Myers Squibb and the 1995 Pegram
Separately, WuXi announced that Mr. Tao Lin, the company's Vice President of Internal Operations since 2002 and a director of the company since 2005, has resigned from the board of directors and as a company officer for personal reasons. Mr. Lin was one of the founders of the company.
''I want to personally thank Tao for his counsel and wisdom while serving on our board,'' said Dr. Li. ''As a founder and key executive of the company, Tao made many contributions to build WuXi from a start-up to the strong company we are today. We all wish him well.''
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
For more information, please contact: Ronald Aldridge Director of Investor Relations WuXi PharmaTech (Cayman) Inc. Tel: +1-215-218-5515 Email: email@example.com
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved